24/7 Market News Snapshot 20 October, 2025 – CorMedix Inc. (NASDAQ:CRMD)
DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (Nasdaq:CRMD) are discussed in this article.
CorMedix Inc. (Nasdaq:CRMD) has shown remarkable growth in both market performance and operational success. The stock opened at $11.78 today and has risen to $12.03, marking an 18.14% increase from the previous close of $10.18. This price movement, alongside a trading volume of 3.26 million shares, indicates significant investor confidence and robust market interest, suggesting positive underlying catalysts, potentially including favorable news or sentiment.
In conjunction with its market performance, CorMedix disclosed substantial financial results for the third quarter of 2025. The company reported preliminary unaudited net revenues exceeding $125 million, largely driven by the successful adoption of DefenCath, which generated over $85 million in revenue. As a result, CorMedix has raised its fiscal year 2025 pro forma net revenue guidance from a forecast of $325-$350 million to a minimum of $375 million. The company anticipates an adjusted EBITDA of at least $70 million for the quarter, underscoring its strong financial position.
Moreover, CorMedix is in the process of integrating the Melinta Therapeutics portfolio, expected to deliver around $30 million in operational synergies by year-end 2025, with prospects for an additional $5 to $15 million by 2026. In terms of clinical advancements, the completion of enrollment in its Phase III ReSPECT study for Rezzayo signifies a crucial step toward addressing fungal infections in patients undergoing allogeneic blood and marrow transplants. Data from this study is set to be released in the second quarter of 2026, with the total addressable market exceeding $2 billion.
As of September 30, 2025, CorMedix reported cash and short-term investments of approximately $56 million, with projections of reaching $100 million by year-end, which positions the company favorably for sustaining its growth trajectory and ongoing innovations in the biopharmaceutical sector.